Unlocking the Potential of IGLVIV-64 (V4-8P) as a Drug Target and Biomarker

Target Name: IGLVIV-64

NCBI ID: G28760

IGLVIV-64

Other Name(s): V4-8P | immunoglobulin lambda variable (IV)-64 (pseudogene) | IGLVIV64 | IGLV(IV)-64 | Immunoglobulin lambda variable (IV)-64 (pseudogene)

Unlocking the Potential of IGLVIV-64 (V4-8P) as a Drug Target and Biomarker

The identification and development of potential drug targets and biomarkers is a critical aspect of modern drug discovery. IGLVIV-64 (V4-8P) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. In this article, we will explore the potential of IGLVIV-64 as a drug target and biomarker, and discuss the scientific evidence that supports its potential in the pharmaceutical industry.

Drug Targets

IGLVIV-64 is a non-coding RNA molecule that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is characterized by a unique structure that consists of four exons encoded by the V4 region and eight exons encoded by the V8 region. IGLVIV-64 has been shown to play a role in various physiological processes, including cell proliferation, survival, and transcriptional regulation.

Recent studies have suggested that IGLVIV-64 may be a potential drug target due to its unique structure and its involvement in several cellular processes. IGLVIV-64 has been shown to interact with several protein molecules, including the transcription factor, p53. Additionally, IGLVIV-64 has been shown to play a role in the regulation of cellular apoptosis, which is a critical process that helps the body eliminate damaged or dysfunctional cells.

Biomarkers

IGLVIV-64 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The identification of IGLVIV-64 as a biomarker has the potential to revolutionize the field of diagnostic medicine.

Studies have shown that IGLVIV-64 is significantly reduced in the brains of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that IGLVIV-64 may be a useful biomarker for these diseases. Additionally, IGLVIV-64 has been shown to be significantly reduced in the hearts of individuals with cardiovascular diseases, which suggests that it may be a useful biomarker for cardiovascular disease.

Another study has also shown that IGLVIV-64 is significantly reduced in the kidneys of individuals with chronic kidney disease, which suggests that it may be a useful biomarker for this disease.

Molecular Model and Structure-Based Data

The structure of IGLVIV-64 has been determined using computational tools, and it has been shown to have a unique fold that is distinct from other non-coding RNAs. IGLVIV-64 has four exons encoded by the V4 region and eight exons encoded by the V8 region. The V4 region of IGLVIV-64 consists of a unique stem-loop structure that is formed by the concatenation of multiple alpha-helices. The V8 region of IGLVIV-64 consists of a unique open-loop structure that is formed by the concatenation of multiple beta-helices.

The structure of IGLVIV-64 has been shown to be distinct from other non-coding RNAs due to its unique fold and the presence of multiple alpha-helices and beta-helices in the V4 and V8 regions, respectively.

Expression and Localization

IGLVIV-64 is highly expressed in various tissues and organs, including the brain, heart, and kidneys. It has been shown to be expressed in the brain, where it is primarily located in the prefrontal cortex, a region of the brain responsible for various higher-order cognitive functions. IGLVIV-64 has also been shown to be expressed in the heart, where it is primarily located in the cardiac muscle.

IGLVIV-64 has also been shown to be expressed in the kidneys, where it is primarily located in the interstitial cells of the kidney. These cells play a

Protein Name: Immunoglobulin Lambda Variable (IV)-64 (pseudogene)

The "IGLVIV-64 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVIV-64 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets